Researchers at the National Institutes of Health (NIH) have developed a new, less invasive way to perform transcatheter aortic valve replacement (TAVR), a procedure widely used to treat aortic valve stenosis, a lethal heart condition. The new approach, called transcaval access, will make TAVR more available to high risk patients, especially women, whose femoral arteries are too small or diseased to withstand the standard procedure. The Journal of the American College of Cardiology published the findings.
New method for performing aortic valve replacement proves successful in high risk patients
↧
↧
Results of PARTNER II QUALITY OF LIFE study presented
Patients with severe aortic stenosis (AS) at intermediate surgical risk, and who are treated with transcatheter aortic valve replacement (TAVR) had improved health status at one month compared with surgical aortic valve replacement (SAVR) but two-year quality of life outcomes were similar. Prior studies have shown that TAVR results in an early quality of life (QoL) benefit in patients at high surgical risk; however, the effect of TAVR versus. SAVR on QoL in intermediate risk patients was unknown prior to this study.
↧
Researchers create exact 3-D models of patients' heart valves to assist cardiologists
Tens of thousands of patients each year are diagnosed with heart valve disease, with many in need of lifesaving surgery to treat the condition.
↧
Women fare better than men one year after valve replacement
Women with significant aortic valve disease who undergo transcatheter aortic valve replacement (TAVR) are considered higher risk than men in some respects. However, their survival rate one year after having had the procedure is higher than men, according to a study published today in the Journal of the American College of Cardiology.
↧
Recs provided for transcatheter aortic valve replacement
(HealthDay)—In a clinical expert consensus report published online Jan. 4 in the Journal of the American College of Cardiology, a series of practice point-of-care checklists help provide guidance on the use of transcatheter aortic valve replacement (TAVR).
↧
↧
STS: SAVR still excellent option for intermediate-risk seniors
(HealthDay)—For intermediate-risk elderly patients, surgical aortic valve replacement (SAVR) remains a safe and effective way to treat aortic stenosis, according to a study presented at the annual meeting of the Society of Thoracic Surgeons, held from Jan. 21 to 25 in Houston.
↧
Furosemide plus matched hydration cuts contrast-induced AKI
(HealthDay)—For high-risk patients undergoing percutaneous coronary intervention or transcatheter aortic valve replacement, furosemide with matched hydration via the RenalGuard system may reduce the incidence of contrast-induced acute kidney injury (CI-AKI), according to a meta-analysis published in the Feb. 27 issue of JACC: Cardiovascular Interventions.
↧
Less invasive procedure may benefit certain heart valve patients
New recommendations clarify which patients who have malfunctioning heart valves may benefit from artificial valves replaced through a minimally invasive procedure; clarify the need for antibiotics for some patients prior to a dental procedure; and expand the age range for choosing tissue valve replacement.
↧
Self-expanding TAVR as good as surgery in intermediate-risk patients
Two-year data reveal no difference in the combined rate of stroke and death from any cause when comparing the use of self-expanding transcatheter aortic valve replacement (TAVR) with standard open-heart surgery in intermediate risk patients with severe aortic stenosis, according to research presented at the American College of Cardiology's 66th Annual Scientific Session. Researchers say these results suggest TAVR, which involves threading a replacement valve through a catheter in the groin or chest, is at least as safe and effective as surgery in these patients.
↧
↧
Embol-X and CardioGard do not reduce overall number of brain lesions, but may affect lesion size
Two FDA-cleared medical devices designed to remove potential vessel-blocking debris particles from the bloodstream during aortic valve replacement, known as Embol-X and CardioGard, did not significantly reduce overall number of brain infarcts over standard surgical procedure, according to a study presented at the American College of Cardiology's 66th Annual Scientific Session.
↧
Heart procedure linked with bleeding in the brain, neurological impairment
Small leakages from blood vessels in the brain, known as microbleeds, increase with age and are associated with cognitive decline. Of 84 older patients undergoing transcatheter aortic valve replacement (TAVR), nearly a quarter developed new microbleeds after their procedure, according to results of a single-center study presented at the American College of Cardiology's 66th Annual Scientific Session.
↧
CT scans reveal reduced leaflet motion after aortic valve replacement
About 12 percent of patients undergoing aortic valve replacement developed non-symptomatic blood clots around the valve leaflets (known as subclinical leaflet thrombosis) that reduced the motion of the valves, according to an observational study presented at the American College of Cardiology's 66th Annual Scientific Session.
↧
Conscious sedation is a safe alternative to general anesthesia for heart valve procedure
UCLA scientists have found that conscious sedation—a type of anesthesia in which patients remain awake but are sleepy and pain-free—is a safe and viable option to general anesthesia for people undergoing a minimally invasive heart procedure called transcatheter aortic valve replacement.
↧
↧
Analysis shows increased risk of early stroke with new-onset atrial fibrillation post-TAVR
More than one-third of patients undergoing transcatheter aortic valve replacement (TAVR) were observed to have atrial fibrillation (AF) either at baseline or new-onset within 30 days after TAVR. Patients with new-onset AF had a >4 fold greater risk of stroke within 30 days. Results from "Effect of bivalirudin versus unfractionated heparin in patients with baseline or new-onset atrial fibrillation in transcatheter aortic valve replacement: From the BRAVO-3 randomized trial" were presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions in New Orleans.
↧
Analysis looks at role type of valve plays in patient outcomes post-TAVR
For patients who undergo transcatheter aortic valve replacement (TAVR), their risk factors, not the type of valve used, determined their 30-day post-TAVR outcomes. Results from "Impact of valve design and bivalirudin vs. unfractionated heparin for anticoagulation in transcatheter aortic valve replacement: Results from the BRAVO-3 trial" were presented today as a late-breaking clinical trial at the Society for CardiovascularAngiography and Interventions (SCAI) 2017 Scientific Sessions in New Orleans.
↧
Neurological events with TAVI and surgical valve replacement in intermediate-risk patients
Patients at intermediate risk for surgery have lower risk of early neurological complications including stroke with transcatheter aortic valve implantation (TAVI) than with surgical aortic valve replacement, showed results reported for the first time at EuroPCR 2017 from the large, randomized SURTAVI (Surgical Replacement and Transcatheter Aortic Valve Implantation) trial.
↧
Nearly one-quarter of patients say mechanical heart valve disturbs sleep
Nearly one-quarter of patients with a mechanical heart valve say it disturbs their sleep, according to research presented today at EuroHeartCare 2017.1
↧
↧
Study implicates two genetic variants in bicuspid aortic valve development
Researchers are working to determine why the aortic valve doesn't form correctly in patients with the most common congenital heart defect: bicuspid aortic valve.
↧
Drug developed for arthritis could be first to stop heart valve calcification
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis.
↧
Study examines use, outcomes of valve replacement procedure performed for off-label indications
Approximately 1 in 10 transcatheter aortic valve replacement (TAVR) procedures in the U.S. were for an off-label indication, with similar 1-year mortality rates compared to on-label use, suggesting that TAVR may be a possible procedure option for certain patients requiring a heart valve replacement, according to a study published by JAMA Cardiology.
↧
Fewer infections in mechanical heart valves
Infections in surgically implanted heart valves are more common in patients who have been given a biological prosthetic valve than in those with a mechanical one, a study from Karolinska Institutet published today in the journal Circulation shows.
↧
↧
Scientists reveal source of human heartbeat in 3-D
A pioneering new study is set to help surgeons repair hearts without damaging precious tissue.
↧
Which TAVR patients are at risk for hospital readmission? Research identifies new prognostic marker
As more elderly patients undergo the minimally invasive heart valve procedure called Transcatheter Aortic Valve Implantation (TAVR), concerns have been raised as to what causes some to be readmitted for heart failure after the procedure.
↧
ESC/EACTS Guidelines for the management of valvular heart disease published today
European Society of Cardiology (ESC) / European Association for Cardio-Thoracic Surgery (EACTS) Guidelines for the management of valvular heart disease are published online today in European Heart Journal and on the ESC website.
↧
Not adhering to recommended exams for severe narrowing of the aortic valve associated with increased heart failure
Patients with asymptomatic severe aortic stenosis who did not follow recommended guidelines for regular exams had poorer survival and were more likely to be hospitalized for heart failure, according to a study published by JAMA Cardiology.
↧
↧
Study shows low mortality and stroke risks for minimally invasive aortic valve replacements
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated procedures over a five-and-a-half year period performed by Dr. Joseph Lamelas, professor and associate chief of cardiac surgery in the division of cardiothoracic surgery at Baylor College of Medicine, showed low stroke rates and high survival rates in all age groups within 30 days of surgery. His report appears in the Journal of Thoracic and Cardiovascular Surgery.
↧
Relatively few kidney patients need to start dialysis after undergoing TAVR
The rate of patients with chronic kidney disease undergoing a heart procedure called transcatheter aortic valve replacement (TAVR) who eventually need to start dialysis is relatively low, suggests a new study published in JACC: Cardiovascular Interventions.
↧
TAVR cost-effective compared with SAVR in intermediate risk patients with aortic stenosis
Analysis of the PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry found transcatheter aortic valve replacement (TAVR) to be highly cost-effective compared with surgical aortic valve replacement (SAVR) in intermediate surgical risk patients with aortic stenosis.
↧
Brain measures tied to atrial pressure in valvular heart Dz
(HealthDay)—For patients with chronic valvular heart disease, white matter hyperintensity (WMH) volume is associated with mean right atrial (RA) pressure, according to a study published online Nov. 6 in JAMA Neurology.
↧
↧
Mechanical heart valve often the safest choice, study says
Mechanical heart valves may be safer in certain cases than valves made of animal tissue and should be used more in heart-valve replacements, especially in younger patients, according to a study by researchers at the Stanford University School of Medicine.
↧
More Pages to Explore .....
